Organon & Co. (OGN) 10-Q2024 Q3 Quarterly report

Filed: 1 Nov 24, 8:06am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: antagonist, Arab, Arabia, ART, assumption, atopic, biologic, candidate, Centergene, children, Colombia, confirmed, cream, dedicated, Dermavant, disease, eczema, entirety, expansion, Food, fusion, GnRH, human, Kuwait, life, men, mild, moderate, Oss, ovarian, peptide, Perjeta, pertuzumab, plaque, presidential, protein, public, Qatar, recombinant, refundable, reproductive, Saudi, South, stimulation, substance, support, Taiwan, tapinarof, territory, tiered, undergoing, Vtama

Removed: accurately, began, buying, core, exposed, February, forecasted, hold, ledger, maintain, module, replace, tender, variable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated OGN transcripts

OGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C.§ 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Organon & Co. fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Organon & Co.

November 1, 2024

/s/ Matthew Walsh

Matthew Walsh

Chief Financial Officer